April 27, 2022 News by Marisa Wexler, MS #AAN2022 – For Children With MS, Symptoms May Predict Future Disability Children with multiple sclerosis (MS) who in their first year after disease onset experience pyramidal symptoms, such as spasticity or weakness, visual problems, or show signs of cerebellum involvement like poorer coordination are more likely to have worse…
April 26, 2022 News by Marisa Wexler, MS #AAN2022 – More Patients Given Ublituximab Relapse-free in Trials More relapsing multiple sclerosis (MS) patients given ublituximab remained relapse-free over the two-year long Phase 3 ULTIMATE clinical trials, compared to those given Aubagio (teriflunomide), new data show. “The prevention of relapses represents an important goal of disease-modifying therapy with the potential…
April 8, 2022 News by Marisa Wexler, MS #AAN2022 – Phase 1 Data Shows NVG-291 Safe; Trial in MS Patients Anticipated NVG-291, an experimental therapy designed to promote nervous system repair, has so far been well tolerated in an ongoing Phase 1 study with healthy volunteers. “The Phase 1 study is progressing very well, and we are encouraged by the…
April 7, 2022 News by Marisa Wexler, MS #AAN2022 – CONSONANCE Update Shows Ocrevus’ Effectiveness After 1 Year Nearly three of every four participants in the CONSONANCE clinical trial, which is evaluating Ocrevus (ocrelizumab) in people with primary or secondary progressive multiple sclerosis (MS), showed no evidence of disease progression after a year of treatment.
April 6, 2022 News by Marisa Wexler, MS #AAN2022 – Data from Multiple Trials Show Kesimpta’s Safety, Efficacy Treatment with Kesimpta (ofatumumab) for more than three years revealed no new or unexpected safety findings, and continued to slow disability progression and prevent the development of new brain lesions in people with relapsing multiple sclerosis (MS),…
April 5, 2022 News by Marta Figueiredo, PhD #AAN2022 – Long-term Evobrutinib Safe, Effective in Relapsing MS Long-term treatment with evobrutinib safely and effectively reduces the rate of relapses in adults with relapsing forms of multiple sclerosis (MS), according to 2.5 years of data from a Phase 2 extension study. These findings — supporting…
April 5, 2022 News by Marisa Wexler, MS #AAN2022 – Ublituximab Bests Aubagio on Disability Measures Ublituximab, an experimental therapy for relapsing multiple sclerosis (MS) patients, outperformed Aubagio on a number of disability-related outcomes in the ULTIMATE clinical trials, new data show. The findings were presented in a series of posters at the…